Investigational Drug Information for BIIB091
✉ Email this page to a colleague
What is the drug development status for BIIB091?
BIIB091 is an investigational drug.
There have been 3 clinical trials for BIIB091.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 2nd 2023.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and [disabled in preview]. The leading clinical trial sponsors are Biogen and [disabled in preview].
Summary for BIIB091
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2023-06-02) |
| Vendors | 0 |
Recent Clinical Trials for BIIB091
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis | Biogen | Phase 2 |
| Study of BIIB091 Formulations in Healthy Participants | Biogen | Phase 1 |
| A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants | Biogen | Phase 1 |
Clinical Trial Summary for BIIB091
Top disease conditions for BIIB091
Top clinical trial sponsors for BIIB091
US Patents for BIIB091
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
